{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T19:04:03Z","timestamp":1773342243392,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00228-025-03937-0","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T03:27:33Z","timestamp":1770780453000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dynamics of long-term adherence to lipid-lowering therapy in patients after myocardial infarction"],"prefix":"10.1007","volume":"82","author":[{"given":"Emil","family":"Hagstr\u00f6m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustaf","family":"Orts\u00e4ter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil","family":"Alml\u00f6f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Vasilevska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margr\u00e9t","family":"Le\u00f3sd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Wettermark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Banefelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders Peter","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"34","key":"3937_CR1","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M et al (2021) 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42(34):3227\u20133337","journal-title":"Eur Heart J"},{"issue":"10263","key":"3937_CR2","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/S0140-6736(20)32233-9","volume":"396","author":"MB Mortensen","year":"2020","unstructured":"Mortensen MB, Nordestgaard BG (2020) Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70\u2013100 years: a contemporary primary prevention cohort. Lancet 396(10263):1644\u20131652","journal-title":"Lancet"},{"issue":"32","key":"3937_CR3","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E et al (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J 38(32):2459\u20132472","journal-title":"Eur Heart J"},{"issue":"1","key":"3937_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12872-017-0659-2","volume":"17","author":"G Journath","year":"2017","unstructured":"Journath G, Hambraeus K, Hagstr\u00f6m E, Pettersson B, L\u00f6thgren M (2017) Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline. BMC Cardiovasc Disord 17(1):1\u20137","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"3937_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al (2020) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS). Eur Heart J 41(1):111\u2013188","journal-title":"Eur Heart J"},{"key":"3937_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-019-1182-5","volume":"19","author":"S Yu","year":"2020","unstructured":"Yu S, Jin J, Chen Z, Luo X (2020) High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients. Lipids Health Dis 19:1\u201314","journal-title":"Lipids Health Dis"},{"issue":"14","key":"3937_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.025813","volume":"11","author":"F Mazhar","year":"2022","unstructured":"Mazhar F, Hjemdahl P, Clase CM, Johnell K, Jernberg T, Sj\u00f6lander A et al (2022) Intensity of and adherence to lipid-lowering therapy as predictors of major adverse cardiovascular outcomes in patients with coronary heart disease. J Am Heart Assoc 11(14):e025813","journal-title":"J Am Heart Assoc"},{"issue":"38","key":"3937_CR8","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A et al (2023) 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European society of cardiology (ESC). Eur Heart J 44(38):3720\u20133826","journal-title":"Eur Heart J"},{"key":"3937_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"290","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al (2019) 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 290:140\u2013205","journal-title":"Atherosclerosis"},{"issue":"6","key":"3937_CR10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3122\/jabfm.2019.06.180313","volume":"32","author":"Q Ngo-Metzger","year":"2019","unstructured":"Ngo-Metzger Q, Zuvekas S, Shafer P, Tracer H, Borsky AE, Bierman AS (2019) Statin use in the U.S. for secondary prevention of cardiovascular disease remains suboptimal. J Am Board Fam Med 32(6):807\u2013817","journal-title":"J Am Board Fam Med"},{"issue":"9493","key":"3937_CR11","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of Statins. Lancet 366(9493):1267\u20131278","journal-title":"Lancet"},{"key":"3937_CR12","doi-asserted-by":"crossref","unstructured":"Svensson MK, Sorio Vilela F, Le\u00f3sd\u00f3ttir M, Banefelt J, Lindh M, Dun AR et al (2022) Effects of lipid-lowering treatment intensity and adherence on cardiovascular outcomes in patients with a recent myocardial infarction: a Swedish register-based study. Ups J Med Sci. ;127","DOI":"10.48101\/ujms.v127.8296"},{"issue":"9","key":"3937_CR13","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","volume":"125","author":"SH Naderi","year":"2012","unstructured":"Naderi SH, Bestwick JP, Wald DS (2012) Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 125(9):882\u20137.e1","journal-title":"Am J Med"},{"issue":"4","key":"3937_CR14","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bcp.12339","volume":"78","author":"MA De Vera","year":"2014","unstructured":"De Vera MA, Bhole V, Burns LC, Lacaille D (2014) Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol 78(4):684\u201398","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"3937_CR15","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.mayocp.2018.01.011","volume":"93","author":"R Ofori-Asenso","year":"2018","unstructured":"Ofori-Asenso R, Zoungas S, Liew D (2018) Reinitiation of statin therapy after discontinuation: a meta-analysis. Mayo Clin Proc 93(5):666\u2013668","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"3937_CR16","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U et al (2007) The new Swedish prescribed drug Register\u2013opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16(7):726\u2013735","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3937_CR17","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C et al (2011) External review and validation of the Swedish National inpatient register. BMC Public Health 11:450","journal-title":"BMC Public Health"},{"issue":"9","key":"3937_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","volume":"32","author":"HL Brooke","year":"2017","unstructured":"Brooke HL, Talback M, Hornblad J, Johansson LA, Ludvigsson JF, Druid H et al (2017) The Swedish cause of death register. Eur J Epidemiol 32(9):765\u201373","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"3937_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10654-019-00511-8","volume":"34","author":"JF Ludvigsson","year":"2019","unstructured":"Ludvigsson JF, Svedberg P, Olen O, Bruze G, Neovius M (2019) The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur J Epidemiol 34(4):423\u2013437","journal-title":"Eur J Epidemiol"},{"key":"3937_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","volume":"31","author":"JF Ludvigsson","year":"2016","unstructured":"Ludvigsson JF, Almqvist C, Bonamy A-KE, Ljung R, Micha\u00eblsson K, Neovius M et al (2016) Registers of the Swedish total population and their use in medical research. Eur J Epidemiol 31:125\u201336","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"3937_CR21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73(5):691\u2013705","journal-title":"Br J Clin Pharmacol"},{"issue":"13","key":"3937_CR22","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.030264","volume":"12","author":"J de Oliveira Costa","year":"2023","unstructured":"de Oliveira Costa J, Lin J, Pearson SA, Buckley NA, Schaffer AL, Falster MO (2023) Persistence and adherence to cardiovascular medicines in Australia. J Am Heart Assoc 12(13):e030264","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"3937_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/02813430802022196","volume":"26","author":"K Johnell","year":"2008","unstructured":"Johnell K, Fastbom J (2008) Multi-dose drug dispensing and inappropriate drug use: a nationwide register-based study of over 700,000 elderly. Scand J Prim Health Care 26(2):86\u201391","journal-title":"Scand J Prim Health Care"},{"issue":"6","key":"3937_CR24","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/gerona\/glx169","volume":"73","author":"R Ofori-Asenso","year":"2018","unstructured":"Ofori-Asenso R, Jakhu A, Zomer E, Curtis AJ, Korhonen MJ, Nelson M et al (2018) Adherence and persistence among statin users aged 65 years and over: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci 73(6):813\u20139","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"3937_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ahj.2022.05.021","volume":"251","author":"F Mazhar","year":"2022","unstructured":"Mazhar F, Hjemdahl P, Clase CM, Johnell K, Jernberg T, Carrero JJ (2022) Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease. Am Heart J 251:78\u201390","journal-title":"Am Heart J"},{"issue":"5","key":"3937_CR26","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1007\/s12325-021-01697-8","volume":"38","author":"I Ahrens","year":"2021","unstructured":"Ahrens I, Khachatryan A, Monga B, Dornstauder E, Sidelnikov E (2021) Association of treatment intensity and adherence to lipid-lowering therapy with major adverse cardiovascular events among post-MI patients in Germany. Adv Ther 38(5):2532\u20132541","journal-title":"Adv Ther"},{"key":"3937_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijcard.2021.03.007","volume":"332","author":"F Schiele","year":"2021","unstructured":"Schiele F, Quignot N, Khachatryan A, Gusto G, Villa G, Kahangire D et al (2021) Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: five years of clinical follow-up from 164,565 post-myocardial infarction patients. Int J Cardiol 332:22\u20138","journal-title":"Int J Cardiol"},{"issue":"2","key":"3937_CR28","first-page":"141","volume":"7","author":"K Khalaf","year":"2021","unstructured":"Khalaf K, Johnell K, Austin PC, Tyden P, Midlov P, Perez-Vicente R et al (2021) Low adherence to statin treatment during the 1st year after an acute myocardial infarction is associated with increased 2nd-year mortality risk-an inverse probability of treatment weighted study on 54 872 patients. Eur Heart J 7(2):141\u20137","journal-title":"Eur Heart J"},{"issue":"11","key":"3937_CR29","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1161\/CIRCULATIONAHA.119.043406","volume":"141","author":"J Brandts","year":"2020","unstructured":"Brandts J, Ray KK (2020) Low density lipoprotein cholesterol\u2013lowering strategies and population health. Circulation 141(11):873\u2013876","journal-title":"Circulation"},{"key":"3937_CR30","unstructured":"Smith MEB, Lee NJ, Haney E, Carson S (2009) Drug class Reviews. Drug class review: HMG-CoA reductase inhibitors (Statins) and Fixed-dose combination products containing a Statin. Final report update 5. Portland (OR): Oregon health & science university copyright \u00a9 2009. Oregon Health & Science University, Portland, Oregon."},{"issue":"6","key":"3937_CR31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676\u201382","journal-title":"Am J Epidemiol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03937-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03937-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03937-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:53:50Z","timestamp":1773309230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03937-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3937"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03937-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Emil Hagstr\u00f6m has received institutional grants from Pfizer, NovoNordisk and Amgen. He has also obtained payment\/honoraria from Amgen, NovoNordisk, Bayer and AstraZeneca for lectures, presentations, participation in advisory board etc. Emil Alml\u00f6f is an employee of Novartis. Anders Peter Larsen is an employee of Novartis. Gustaf Orts\u00e4ter is an employee of Quantify Research and owns Quantify Research stocks and stock options. Jonas Banefelt is an employee of Quantify Research and owns Quantify Research stocks and stock options. Marija Vasilevska is an employee of Quantify Research. Quantify Research AB provides consulting and other research services to pharmaceutical, medical device, and related organizations. Quantify Research AB received funding from Novartis AB to conduct this study and for the development of this manuscript. Margr\u00e9t Le\u00f3sd\u00f3ttir has received institutional grants and honoraria from Amarin, Amgen, AstraZeneca, Bonnier Health Care, NovoNordisk and Sanofi outside the submitted work. Bj\u00f6rn Wettermark has no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}